# NuProbe

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nuprobe

- Industry: Biotechnology
- Headquarters: Houston, US
- Website: www.nuprobe.com
- Total disclosed funding: $11M
- Latest round: Series A (Apr 23, 2018)
- Investors on record: 3

## About

NuProbe, Inc. focuses on innovative genomic technologies that enhance the sensitivity of DNA biomarker assays, particularly in oncology research, providing advanced tools for laboratories.NuProbe, Inc., founded in 2016, is based in Houston, US. The company specializes in genomic technologies and was formed following a merger with Carrier Gene in January 2020. The founders include Chai Yingshuang, David Zhang, Junfeng Luo, and Peng Yin, with Chai Yingshuang serving as CEO. The company has received funding through 2 deals, with the most recent being a Series A round in which it raised USD 11.00 mn from investors including Sequoia Capital, Serica Partners, and Wuxi AppTec Group. The total amount raised by NuProbe stands at USD 11.00 mn.NuProbe develops advanced genomic technologies that improve the sensitivity of analytical assays for DNA biomarkers, particularly in oncology. Key offerings include Blocker Displacement Amplification (BDA) technology, enabling selective amplification of low-abundance sequence variants down to a variant allele frequency (VAF) of 0.01%, and the QASeq platform for ultrahigh-sensitivity detection of copy number variations and mutations from FFPE tissue and cfDNA. These products cater to research laboratories focusing on genomics and molecular diagnostics in the US and China.NuProbe operates on a B2B model, primarily serving research institutions and laboratories. The company generates revenue through partnerships and licensing agreements, including an exclusive arrangement with Bio-Rad for digital PCR applications. Institutions purchase assay kits and services tailored to their research needs, with flagship products like the VarTrace series and QASeq technology. Although specific pricing information is not disclosed, NuProbe's offerings are positioned as high-value solutions in the genomics market.NuProbe plans to expand its product offerings and geographic presence. The company is focused on developing new products aimed at enhancing genomic research capabilities, although specific product release dates were not mentioned. NuProbe is also targeting expansion into additional markets, particularly in the United States and China, by leveraging recent funding. The Series A funding, completed in January 2020, will support these initiatives and facilitate growth in its operational framework.

## Funding rounds

- Series A, Apr 23, 2018, $11M — Hong Shan, Serica Partners, Wuxi AppTec Group

## Investors

- Hong Shan — Series A
- Serica Partners — Series A
- Wuxi AppTec Group — Series A